aripiprazole has been researched along with Weight Gain in 95 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 30 (31.58) | 29.6817 |
| 2010's | 51 (53.68) | 24.3611 |
| 2020's | 14 (14.74) | 2.80 |
| Authors | Studies |
|---|---|
| Ernsberger, P; Hufeisen, SJ; Jayathilake, K; Kroeze, WK; Meltzer, HY; Popadak, BA; Renock, SM; Roth, BL; Steinberg, S | 1 |
| Huang, AS; Kim, SF; Snowman, AM; Snyder, SH; Teuscher, C | 1 |
| Coolen, HK; Glennon, JC; Kruse, CG; Lange, JH; Reinders, JH; Tolboom, JT | 1 |
| Chen, J; Chen, Y; Gao, L; Hao, C; Jin, J; Liu, BF; Liu, X; Ma, R; Wu, Q; Zhang, G; Zheng, L | 1 |
| Dragovic, M; Hacking, D; Hulme, D; Parmar, A; Shymko, G; Terina, G; Waters, F | 1 |
| Ahmed, NJ; Alahmari, A; Almalki, ZS; Alshehri, AM | 1 |
| de Winter, BCM; Dierckx, B; Hermans, RA; Hillegers, MHJ; Kloosterboer, SM; Koch, BCP; Liang, K; Ringeling, LT | 1 |
| Cheng, Z; Gao, T; Huang, B; Huang, Z; Pu, C; Shi, C; Yu, X; Zhang, D; Zheng, Y; Zhou, E; Zhou, T | 1 |
| Bastiaansen, D; de Kroon, MMJ; de Winter, BCM; Dierckx, B; Hermans, RA; Hillegers, MHJ; Kloosterboer, SM; Koch, BCP; Kouijzer, MEJ; Nasserinejad, K; Reichart, CG; Sassen, SDT; van Altena, D; van Schaik, RHN | 1 |
| Cohen, D; Veerman, SRT | 1 |
| Munayco Maldonado, GM; Schwartz, TL | 1 |
| Iyer, S; Joober, R; Lepage, M; Malla, A; Mustafa, S; Shah, J | 1 |
| Bai, Y; Chen, G; Gao, K; Yang, H | 1 |
| Ikuta, T; Iwata, N; Kishi, T; Matsuda, Y; Sakuma, K | 1 |
| Dobson, L; Grace, T; Hacking, D; Jolly, N; Kapi, P; Parmar, A; Shymko, G; Waters, F | 1 |
| Ayesa Arriola, R; Crespo Facorro, B; Gómez Revuelta, M; Ibáñez Alario, M; Juncal Ruiz, M; Mayoral-van Son, J; Ortiz-García de la Foz, V; Vázquez-Bourgon, J | 1 |
| Cohen, D; Coustals, N; Ménard, ML | 1 |
| Alisauskiene, R; Anda, LG; Bartz-Johannessen, C; Berle, JØ; Bjarke, J; Fathian, F; Fleischhacker, WW; Hugdahl, K; Joa, I; Johnsen, E; Kjelby, E; Kroken, RA; Larsen, TK; Løberg, EM; Reitan, SK; Rettenbacher, M; Sinkeviciute, I; Skrede, S; Stabell, L; Steen, VM; Walla, B | 1 |
| Barber, S; Cipriani, A; Corsi, M; Olotu, U | 1 |
| DeGuzman, MC; Frank, GK; Hagman, JO; Rossi, B; Schiel, MA; Shott, ME | 1 |
| Bilenberg, N; Correll, CU; Fagerlund, B; Fink-Jensen, A; Gluud, C; Jantzen, P; Jensen, KG; Jeppesen, P; Jepsen, JRM; Klauber, DG; Lange, T; Lauritsen, MG; Madsen, S; Nyvang, L; Pagsberg, AK; Rasmussen, S; Rudå, D; Saldeen, EA; Skoog, M; Stenstrøm, AD; Stentebjerg-Olesen, M; Werge, TM; Winkel, P | 1 |
| Aquila, R; Jamal, HH; Nasrallah, HA; Risinger, R; Stanford, AD; Weiden, PJ | 1 |
| Cameron, C; Desai, D; Drake, C; Hutton, B; Kotb, A; Weiden, PJ; Zummo, J | 1 |
| Bota, RG; Hazen, J; Howard, P; Nguyen, C; Novac, A; Tieu, R | 1 |
| Ahuja, N; Gottfried, J; Rabinowitz, SS | 1 |
| Baker, RA; Duffy, RA; Gwin, KK; McQuade, RD; Weiller, E; Weiss, C; Zhang, P | 1 |
| Aguiar, PM; de Mendonça Lima, T; Ribeiro, ELA; Storpirtis, S; Vieira, MEB | 1 |
| Amatniek, J; Calabrese, JR; Carson, WH; Cox, K; Hertel, P; Jin, N; Johnson, B; McQuade, RD; Nyilas, M; Perry, PP; Sanchez, R; Such, P | 1 |
| Bernardini, R; Biganzoli, E; Bravaccio, C; Capuano, A; Carnovale, C; Clementi, E; Marano, G; Molteni, M; Nobile, M; Pisano, S; Pozzi, M; Radice, S; Rafaniello, C; Rizzo, R; Rossi, F | 1 |
| Beex-Oosterhuis, MM; Dieleman, HG; Eussen, MLJM; Schoemakers, RJ; van Kesteren, C; van Rosmalen, J | 1 |
| Correll, CU; Decara, MS; Eriksson, F; Fagerlund, B; Fink-Jensen, A; Jensen, KG; Jepsen, JRM; Klauber, DG; Pagsberg, AK; Rudå, D | 1 |
| Bougie, J; Clerzius, G; Malla, A; Miguelez, M; Mustafa, S; Proulx, J; Rampakakis, E | 1 |
| Lenze, EJ; Locke, AE; Miller, JP; Müller, DJ; Mulsant, BH; Newcomer, JW; Nicol, GE; Oughli, H; Peterson, TR; Reynolds, CF; Yingling, MD; Zhong, Y | 1 |
| Abramson, RK; Bradley, C; Bragg, JE; Carpenter, LA; Charles, JM; DeVane, CL; Donovan, JL; Geesey, ME; Gwynette, F; Hall, AG; Kinsman, A; Kruesi, MJ; Powers, NR; Raven, S; Sherk, ST; Spratt, E; Stuck, CA; Williams, JE | 1 |
| Beccarini Crescenzi, B; Bolognesi, S; Cuomo, A; Facchi, E; Fagiolini, A; Giordano, N; Goracci, A; Neal, SM; Rossi, R | 1 |
| Aitchison, KJ; Almandil, NB; Besag, FM; Liu, Y; Murray, ML; Wong, IC | 1 |
| Baker, RA; Carson, W; Fleischhacker, WW; Forbes, RA; Jin, N; Johnson, B; Kane, JM; McQuade, R; Sanchez, R | 1 |
| Fuller, C; Grudziak, J; Nguyen, HL; Rickels, K; Rickels, MR; Teff, KL | 1 |
| Aida, SA; Hatim, A; Mohamed, Z; Reynolds, GP; Roffeei, SN; Said, MA; Zainal, NZ | 1 |
| Dai, G; Zhang, Y | 1 |
| Early, M; Erickson, CA; Horn, P; McDougle, CJ; Pottenger, A; Schaefer, T; Wink, LK | 1 |
| Baker, RA; Citrome, L; Hebden, T; Kalsekar, I | 1 |
| De Santis, M; Deng, C; Huang, XF; Lian, J; Pan, B | 1 |
| Gu, N; Kane, JM; Li, H; Luo, J; Wang, C; Wang, X; Xie, S; Xu, X; Yu, W | 1 |
| Amado, JA; Ayesa-Arriola, R; Crespo-Facorro, B; Garcia-Unzueta, MT; Martínez García, O; Ortiz-Garcia de la Foz, V; Pérez-Iglesias, R; Suarez-Pinilla, P; Tabares-Seisdedos, R | 1 |
| Fujii, Y; Ishigooka, J; Iwata, N; Iyo, M; Kishimoto, T; Nakamura, J; Nishimura, R; Shimizu, N; Uchimura, N | 1 |
| Gopal, S; Hough, D; Lane, R; Nuamah, I; Savitz, AJ | 1 |
| Baglivo, V; Balestrieri, M; Brambilla, P; Gregoraci, G; Isola, M; Meduri, M | 1 |
| Culhane, C; Hope, J; Keks, NA | 1 |
| Baker, RA; Citrome, L; Nagamizu, K; Ota, A; Perry, P; Weiller, E | 1 |
| Abadi, S; Joober, R; Lepage, M; Malla, A; Mustafa, S; Rho, A | 1 |
| Chang, KD | 1 |
| Anderson, SJ; Brady, KT; McRae, AL; Tolliver, BK; Verduin, ML | 1 |
| Libiger, J; Masopust, J; Tůma, I | 1 |
| Carson, WH; Cutler, AJ; Keck, PE; Marcus, RN; McQuade, RD; Orsulak, PJ; Sanchez, R; Torbeyns, A | 1 |
| Bogers, JP; Starrenburg, FC | 1 |
| Englisch, S; Inta, D; Weinbrenner, A; Zink, M | 1 |
| Baker, RA; Berman, RM; Fava, M; Marcus, RN; Pikalov, A; Thase, ME; Tran, QV; Wisniewski, SR; Yang, H | 1 |
| Correll, CU; Kane, JM; Malhotra, AK; Manu, P; Napolitano, B; Olshanskiy, V | 1 |
| Carson, WH; Corey-Lisle, P; Findling, RL; Manos, G; Marcus, RN; McQuade, RD; Owen, R; Sikich, L | 1 |
| Stip, E; Tourjman, V | 1 |
| Roxanas, MG | 1 |
| Chen, J; Deng, C; Hu, C; Huang, XF | 1 |
| Davis, JM; Hunger, H; Kissling, W; Komossa, K; Leucht, S; Lobos, CA; Rummel-Kluge, C; Schmid, F; Schwarz, S | 1 |
| Case, M; Conley, RR; Hoffmann, VP; Jacobson, JG; Stauffer, VL | 1 |
| Correll, CU | 1 |
| Lee, SY; Pae, CU; Park, MH; Patkar, AA | 1 |
| Cohn, T; Faulkner, G; Mukundan, A; Remington, G | 1 |
| Bang, L; Harris, TB; Mian, A; Muscal, E | 1 |
| Hou, YC; Lai, CH | 1 |
| Carson, WH; Findling, RL; Kamen, L; Mankoski, R; Manos, G; Marcus, RN; McQuade, RD; Owen, R | 1 |
| Calabrese, JR; Demeter, CA; Findling, RL; Frazier, TW; Lingler, J; McNamara, NK; Otto, BD; Rowles, BM; Stansbrey, RJ; Youngstrom, EA | 1 |
| Berge, RK; Diéguez, C; Fernø, J; Fjær, S; López, M; Lunder, N; Pavlin, T; Skrede, S; Steen, VM; Vázquez, MJ; Vidal-Puig, A | 1 |
| Fava, M; Flynn, M; Harper, L; Iosifescu, D; Levy, M; Mischoulon, D; Pencina, M; Pollack, M; Rickels, K; Witte, J | 1 |
| Croxtall, JD | 1 |
| Chen, CK; Hsiao, CC; Huang, YS; Ree, SC; Wang, LJ | 1 |
| Bryois, Ch; Sahli, Ch | 1 |
| Citrome, L; Volavka, J | 1 |
| Archibald, D; Carson, WH; Gharbia, NA; Jody, D; Marcus, R; McQuade, RD; Stock, E; Vanveggel, S | 1 |
| Connor, KM; Davidson, JR; Gadde, KM; Payne, VM; Zhang, W | 1 |
| Britt, CS; Daniels, AJ; Grizzle, MK; Ignar, DM; Jones, DN; Kalinichev, M; Rourke, C | 1 |
| Bahta, E; Levine, S; Manas, K; Reddymasu, S; Slay, LE | 1 |
| Chen, CK; Lin, SK | 1 |
| Chavez, B; Poveda, RA | 1 |
| Banki, CM; Beuzen, JN; Hanssens, L; Herman, E; Kerwin, R; L'Italien, G; Lublin, H; McQuade, RD; Millet, B; Pans, M | 1 |
| Abbasi, FA; Glick, ID; Ivanova, O; Kim, SH; Lamendola, CA; Reaven, GM | 1 |
| Chen, CH; Huang, MC; Lu, ML | 1 |
| Cooper, T; Usubiaga, H; Winsberg, B | 1 |
| Perlis, RH | 1 |
| Neill, JC; Reynolds, GP; Snigdha, S; Thumbi, C | 1 |
| Berman, RM; Carson, WH; Fava, M; Hennicken, D; Marcus, RN; McQuade, RD; Simon, JS; Thase, ME; Trivedi, MH | 1 |
| Burne, TH; Deng, C; Han, M; Huang, XF; Newell, KA | 1 |
24 review(s) available for aripiprazole and Weight Gain
| Article | Year |
|---|---|
Aripiprazole in young people with early psychosis: a systematic review and meta-analysis of weight gain.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Humans; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Schizophrenia; Weight Gain | 2022 |
[Prevention and treatment of antipsychotic induced weight gain].
Topics: Antipsychotic Agents; Aripiprazole; Humans; Metformin; Topiramate; Weight Gain | 2023 |
Differentiating the third generation of antipsychotics: a focus on lumateperone's similarities and differences.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Humans; Schizophrenia; Weight Gain | 2024 |
Do Asian and North American patients with bipolar disorder have similar efficacy, tolerability, and safety profile during clinical trials with atypical antipsychotics?
Topics: Adult; Antipsychotic Agents; Aripiprazole; Asian People; Bipolar Disorder; Female; Humans; North America; Olanzapine; Quetiapine Fumarate; Risperidone; United States; Weight Gain | 2020 |
Aripiprazole vs. brexpiprazole for acute schizophrenia: a systematic review and network meta-analysis.
Topics: Acute Disease; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Humans; Network Meta-Analysis; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Thiophenes; Weight Gain | 2020 |
Aripiprazole in Children and Adolescents.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Child; Drug-Related Side Effects and Adverse Reactions; Humans; Off-Label Use; Schizophrenia; Tourette Syndrome; Weight Gain | 2021 |
Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia.
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Clozapine; Dibenzothiazepines; Drug Resistance; Drug Therapy, Combination; Female; Haloperidol; Humans; Male; Piperazines; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Sulpiride; Thiazoles; Weight Gain | 2017 |
Efficacy and safety of aripiprazole lauroxil once-monthly versus aripiprazole once-monthly long-acting injectable formulations in patients with acute symptoms of schizophrenia: an indirect comparison of two double-blind placebo-controlled studies.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Bayes Theorem; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Male; Network Meta-Analysis; Randomized Controlled Trials as Topic; Schizophrenia; Weight Gain | 2018 |
Efficacy and safety of aripiprazole for the treatment of schizophrenia: an overview of systematic reviews.
Topics: Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Cholesterol; Glucose Metabolism Disorders; Humans; Lipid Metabolism; Schizophrenia; Treatment Outcome; Weight Gain | 2018 |
Drug safety evaluation of aripiprazole in bipolar disorder.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Delayed-Action Preparations; Humans; Weight Gain | 2019 |
Weight gain and other metabolic adverse effects associated with atypical antipsychotic treatment of children and adolescents: a systematic review and meta-analysis.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Humans; Olanzapine; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Weight Gain | 2013 |
A review of real-world data on the effects of aripiprazole on weight and metabolic outcomes in adults.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Carbohydrate Metabolism; Diabetes Mellitus; Glucose Metabolism Disorders; Humans; Hyperlipidemias; Insulin Resistance; Lipid Metabolism; Overweight; Piperazines; Quinolones; Weight Gain | 2014 |
A meta-analysis of efficacy and safety of aripiprazole in adult and pediatric bipolar disorder in randomized controlled trials and observational studies.
Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Bipolar Disorder; Child; Gastrointestinal Diseases; Humans; Hyperprolactinemia; Male; Middle Aged; Observational Studies as Topic; Randomized Controlled Trials as Topic; Treatment Outcome; Weight Gain; Young Adult | 2016 |
The use of atypical antipsychotics in pediatric bipolar disorder.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Bipolar Disorder; Child; Comorbidity; Dibenzothiazepines; Disorders of Excessive Somnolence; Humans; Obesity; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Thiazoles; Weight Gain | 2008 |
How can antipsychotics cause Diabetes Mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins.
Topics: Adiponectin; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Clozapine; Diabetes Mellitus; Humans; Leptin; Obesity; Olanzapine; Piperazines; Quinolones; Receptor, Muscarinic M3; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Receptors, Histamine; Serotonin 5-HT1 Receptor Agonists; Thiazoles; Weight Gain | 2009 |
Metabolic assessment of aripiprazole as adjunctive therapy in major depressive disorder: a pooled analysis of 2 studies.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Aripiprazole; Biomarkers; Blood Glucose; Body Mass Index; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Lipid Metabolism; Lipids; Logistic Models; Male; Metabolic Diseases; Middle Aged; Multicenter Studies as Topic; Obesity; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Treatment Outcome; Waist Circumference; Weight Gain; Young Adult | 2009 |
Aripiprazole in schizophrenia and schizoaffective disorder: A review.
Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Middle Aged; Nausea; Piperazines; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Sleep Initiation and Maintenance Disorders; Treatment Outcome; Weight Gain; Young Adult | 2010 |
Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Cholesterol; Clinical Trials as Topic; Clozapine; Dibenzothiazepines; Humans; Imidazoles; Indoles; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Sulpiride; Thiazoles; Weight Gain | 2010 |
Switching and combining antipsychotics.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Decision Making; Female; Humans; Olanzapine; Piperazines; Polypharmacy; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology; Weight Gain | 2010 |
Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Body Mass Index; Body Weight; Dibenzothiazepines; Drug Substitution; Fasting; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Schizophrenia; Weight Gain | 2010 |
Aripiprazole: a review of its use in the management of schizophrenia in adults.
Topics: Adult; Age Factors; Antipsychotic Agents; Aripiprazole; Humans; Hyperglycemia; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology; Weight Gain | 2012 |
[Psychotropics and weight gain].
Topics: Adolescent; Adult; Amisulpride; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Child; Clozapine; Dibenzothiazepines; Double-Blind Method; Female; Fructose; Haloperidol; Humans; Imidazoles; Indoles; Male; Obesity; Olanzapine; Piperazines; Placebos; Psychotropic Drugs; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Socioeconomic Factors; Sulpiride; Thiazoles; Time Factors; Topiramate; Valproic Acid; Weight Gain | 2004 |
The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Diabetes Mellitus, Type 2; Dibenzothiazepines; Drug Administration Schedule; Humans; Hyperprolactinemia; Mental Disorders; Olanzapine; Patient Compliance; Piperazines; Practice Guidelines as Topic; Prescription Fees; Quetiapine Fumarate; Quinolones; Risk Assessment; Risperidone; Thiazoles; Torsades de Pointes; Treatment Outcome; Weight Gain | 2004 |
Treatment of bipolar disorder: the evolving role of atypical antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Arrhythmias, Cardiac; Benzodiazepines; Bipolar Disorder; Diabetes Mellitus, Type 2; Dibenzothiazepines; Drug Evaluation; Drug Interactions; Drug Therapy, Combination; Dyslipidemias; Humans; Hyperprolactinemia; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Thiazoles; Treatment Outcome; Weight Gain | 2007 |
31 trial(s) available for aripiprazole and Weight Gain
| Article | Year |
|---|---|
The effect of therapeutic drug monitoring of risperidone and aripiprazole on weight gain in children and adolescents: the SPACe 2: STAR (trial) protocol of an international multicentre randomised controlled trial.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Drug Monitoring; Humans; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Risperidone; Weight Gain | 2022 |
Early Stabilization of Weight Changes Following Treatment With Olanzapine, Risperidone, and Aripiprazole: A 12-Month Naturalistic Study of First Episode Psychosis.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Body Mass Index; Female; Humans; Male; Olanzapine; Prospective Studies; Psychotic Disorders; Risperidone; Time Factors; Weight Gain; Young Adult | 2019 |
A 3-year prospective study on the metabolic effect of aripiprazole, quetiapine and ziprasidone: A pragmatic clinical trial in first episode psychosis patients.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Energy Metabolism; Female; Follow-Up Studies; Humans; Longitudinal Studies; Male; Piperazines; Prospective Studies; Psychotic Disorders; Quetiapine Fumarate; Schizophrenia; Thiazoles; Time Factors; Weight Gain; Young Adult | 2020 |
Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): a pragmatic, rater-blind, semi-randomised trial.
Topics: Adolescent; Adult; Aged; Amisulpride; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Middle Aged; Norway; Olanzapine; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Treatment Outcome; Weight Gain; Young Adult | 2020 |
Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Delayed-Action Preparations; Denmark; Double-Blind Method; Female; Humans; Male; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Regression Analysis; Treatment Outcome; Weight Gain | 2017 |
Metabolic and Endocrine Profiles During 1-Year Treatment of Outpatients with Schizophrenia with Aripiprazole Lauroxil.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Blood Glucose; Cholesterol; Delayed-Action Preparations; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Injections, Intramuscular; Male; Middle Aged; Outpatients; Prolactin; Schizophrenia; Triglycerides; Weight Gain; Young Adult | 2017 |
The safety and tolerability of aripiprazole once-monthly as maintenance treatment for bipolar I disorder: A double-blind, placebo-controlled, randomized withdrawal study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Conduct Disorder; Double-Blind Method; Female; Humans; Maintenance Chemotherapy; Male; Middle Aged; Psychomotor Agitation; Substance Withdrawal Syndrome; Weight Gain; Young Adult | 2018 |
Cardiometabolic Adverse Effects and Its Predictors in Children and Adolescents With First-Episode Psychosis During Treatment With Quetiapine-Extended Release Versus Aripiprazole: 12-Week Results From the Tolerance and Effect of Antipsychotics in Children
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Body Mass Index; Child; Delayed-Action Preparations; Denmark; Double-Blind Method; Female; Humans; Male; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Regression Analysis; Treatment Outcome; Weight Gain | 2019 |
Real-life assessment of aripiprazole monthly (Abilify Maintena) in schizophrenia: a Canadian naturalistic non-interventional prospective cohort study.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Brief Psychiatric Rating Scale; Canada; Cohort Studies; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prospective Studies; Schizophrenia; Schizophrenic Psychology; Treatment Outcome; Weight Gain; Young Adult | 2019 |
Getting to precision psychopharmacology: Combining clinical and genetic information to predict fat gain from aripiprazole.
Topics: Absorptiometry, Photon; Adiposity; Aged; Antidepressive Agents; Aripiprazole; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Genome-Wide Association Study; Humans; Male; Polymorphism, Single Nucleotide; Venlafaxine Hydrochloride; Weight Gain | 2019 |
Pharmacotherapy of Autism Spectrum Disorder: Results from the Randomized BAART Clinical Trial.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Autism Spectrum Disorder; Child; Double-Blind Method; Female; Humans; Male; Risperidone; Treatment Outcome; Weight Gain | 2019 |
Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Early Termination of Clinical Trials; Humans; Incidence; Injections, Intramuscular; Maintenance Chemotherapy; Middle Aged; Piperazines; Quinolones; Schizophrenia; Sleep Initiation and Maintenance Disorders; Weight Gain; Young Adult | 2013 |
Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Eating; Female; Humans; Insulin Resistance; Male; Mental Disorders; Olanzapine; Piperazines; Postprandial Period; Quinolones; Weight Gain; Young Adult | 2013 |
Association of ADRA2A and MTHFR gene polymorphisms with weight loss following antipsychotic switching to aripiprazole or ziprasidone.
Topics: Adult; Alleles; Antipsychotic Agents; Aripiprazole; Body Mass Index; Female; Follow-Up Studies; Genotype; Humans; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Piperazines; Polymorphism, Genetic; Quinolones; Receptors, Adrenergic, alpha-2; Schizophrenia; Thiazoles; Weight Gain; Weight Loss | 2014 |
Efficacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone to patients with first-episode schizophrenia through 52 weeks follow-up in China.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Body Mass Index; China; Delayed-Action Preparations; Diagnostic and Statistical Manual of Mental Disorders; Female; Follow-Up Studies; Humans; Hyperglycemia; Hyperlipidemias; Isoxazoles; Male; Metabolic Diseases; Paliperidone Palmitate; Piperazines; Psychiatric Status Rating Scales; Pyrimidines; Quinolones; Schizophrenia; Thiazoles; Weight Gain; Young Adult | 2012 |
Efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects: a randomized, double-blind, active parallel-controlled, multicenter clinical trial.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Asian People; Blood Pressure; China; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Electrocardiography; Female; Heart Rate; Humans; Hyperprolactinemia; Male; Piperazines; Psychiatric Status Rating Scales; Quinolones; Risperidone; Schizophrenia; Treatment Outcome; Weight Gain | 2014 |
Comparison of metabolic effects of aripiprazole, quetiapine and ziprasidone after 12 weeks of treatment in first treated episode of psychosis.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cholesterol; Dibenzothiazepines; Female; Follow-Up Studies; Humans; Male; Piperazines; Prolactin; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Sex Factors; Thiazoles; Weight Gain | 2014 |
Efficacy and safety of aripiprazole once-monthly in Asian patients with schizophrenia: a multicenter, randomized, double-blind, non-inferiority study versus oral aripiprazole.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Asian People; Double-Blind Method; Drug Administration Schedule; Female; Humans; Injections; Japan; Kaplan-Meier Estimate; Malaysia; Male; Philippines; Psychiatric Status Rating Scales; Schizophrenia; Taiwan; Treatment Outcome; Weight Gain | 2015 |
Efficacy and safety of paliperidone extended release in adolescents with schizophrenia: a randomized, double-blind study.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Delayed-Action Preparations; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Europe; Female; Headache; Humans; India; Male; Paliperidone Palmitate; Psychiatric Status Rating Scales; Psychomotor Agitation; Schizophrenia; Severity of Illness Index; Treatment Outcome; United States; Weight Gain | 2015 |
The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia: results from a randomized, exploratory study.
Topics: Acute Disease; Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Quinolones; Schizophrenia; Serotonin Agents; Thiophenes; Treatment Outcome; Weight Gain | 2016 |
Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Female; Follow-Up Studies; Headache; Humans; Lithium Compounds; Male; Middle Aged; Nausea; Piperazines; Placebos; Psychiatric Status Rating Scales; Quinolones; Severity of Illness Index; Treatment Outcome; Weight Gain | 2009 |
Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Autistic Disorder; Child; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Irritable Mood; Male; Personality Assessment; Piperazines; Quinolones; Treatment Outcome; Weight Gain | 2009 |
Predictive value of early changes in triglycerides and weight for longer-term changes in metabolic measures during olanzapine, ziprasidone or aripiprazole treatment for schizophrenia and schizoaffective disorder post hoc analyses of 3 randomized, controll
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Cholesterol; Drug Monitoring; Female; Humans; Male; Middle Aged; Olanzapine; Piperazines; Quinolones; Schizophrenia; Thiazoles; Time Factors; Triglycerides; Weight Gain | 2010 |
Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, open-label, multicenter study.
Topics: Adolescent; Aggression; Alanine Transaminase; Antipsychotic Agents; Aripiprazole; Aspartate Aminotransferases; Autistic Disorder; Basal Ganglia Diseases; Child; Drug Tolerance; Female; Humans; Irritable Mood; Male; Piperazines; Quinolones; Weight Gain | 2011 |
An open-label study of aripiprazole in children with a bipolar disorder.
Topics: Antipsychotic Agents; Aripiprazole; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Central Nervous System Stimulants; Child; Child, Preschool; Comorbidity; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Male; Outpatients; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Treatment Outcome; Weight Gain | 2011 |
A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study).
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Constipation; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Models, Statistical; Piperazines; Placebos; Quinolones; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome; United States; Weight Gain; Young Adult | 2012 |
A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Double-Blind Method; Female; Humans; Hyperlipidemias; Incidence; Lipids; Male; Obesity; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Treatment Outcome; Weight Gain | 2004 |
The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Drug Administration Schedule; Humans; Male; Nausea; Obesity; Obsessive-Compulsive Disorder; Pilot Projects; Piperazines; Psychiatric Status Rating Scales; Quinolones; Treatment Outcome; Weight Gain | 2005 |
A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Blood Glucose; Community Mental Health Services; Female; Humans; Lipoproteins; Male; Middle Aged; Patient Care; Piperazines; Prolactin; Quality of Life; Quinolones; Schizophrenia; Severity of Illness Index; Weight Gain | 2007 |
Ghrelin and leptin response to oral glucose challenge among antipsychotic drug-treated children.
Topics: Administration, Oral; Adolescent; Age Factors; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Blood Glucose; Body Mass Index; Child; Chlorpromazine; Fasting; Female; Ghrelin; Glucose; Glucose Tolerance Test; Humans; Insulin; Leptin; Male; Piperazines; Quinolones; Risperidone; Sex Factors; Time Factors; Weight Gain | 2007 |
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents; Aripiprazole; Citalopram; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Fatigue; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Sertraline; Single-Blind Method; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride; Weight Gain; Withholding Treatment | 2008 |
40 other study(ies) available for aripiprazole and Weight Gain
| Article | Year |
|---|---|
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.
Topics: Animals; Antipsychotic Agents; Discriminant Analysis; Drug Evaluation, Preclinical; Forecasting; Humans; Protein Binding; Receptors, Histamine H1; Statistics, Nonparametric; Weight Gain | 2003 |
From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase.
Topics: Adenylate Kinase; Animals; Antipsychotic Agents; Enzyme Activation; Hypothalamus; Immunohistochemistry; Mice; Phosphorylation; Receptors, Histamine H1; Weight Gain | 2007 |
Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzoxazines; Biogenic Monoamines; Humans; Hyperprolactinemia; Indoles; Metabolic Diseases; Phthalimides; Piperazines; Principal Component Analysis; Pyridines; Radioligand Assay; Receptors, Biogenic Amine; Weight Gain | 2007 |
Discovery of a new class of multi-target heterocycle piperidine derivatives as potential antipsychotics with pro-cognitive effect.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Cognition; Dopamine; Drug Design; Humans; Hyperprolactinemia; Mice; Models, Animal; Movement; Piperidines; Protein Binding; Receptors, Histamine H3; Risperidone; Serotonin; Structure-Activity Relationship; Weight Gain | 2021 |
Drug-induced weight gain in the last 10 years: a descriptive study.
Topics: Adalimumab; Adverse Drug Reaction Reporting Systems; Aripiprazole; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Etanercept; Humans; Prednisone; Pregabalin; Retrospective Studies; Risperidone; United States; Weight Gain | 2022 |
Weight changes following treatment with aripiprazole, risperidone and olanzapine: A 12-month study of first-episode schizophrenia patients in China.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Weight; Humans; Olanzapine; Risperidone; Schizophrenia; Weight Gain | 2023 |
Towards precision dosing of aripiprazole in children and adolescents with autism spectrum disorder: Linking blood levels to weight gain and effectiveness.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Autism Spectrum Disorder; Body Mass Index; Child; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Weight Gain | 2023 |
Weight gain and metabolic screening in young people with early psychosis on long acting injectable antipsychotic medication (aripiprazole vs paliperidone).
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Humans; Paliperidone Palmitate; Psychotic Disorders; Schizophrenia; Weight Gain | 2021 |
The partial dopamine D2 receptor agonist aripiprazole is associated with weight gain in adolescent anorexia nervosa.
Topics: Adolescent; Anorexia Nervosa; Aripiprazole; Body Mass Index; Dopamine Agonists; Female; Humans; Receptors, Dopamine D2; Retrospective Studies; Reward; Treatment Outcome; Weight Gain | 2017 |
Weight gain changes in patients with aripiprazole monotherapy compared with aripiprazole-antidepressant polypharmacy in an outpatient sample.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Body Mass Index; Cohort Studies; Depression; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Mood Disorders; Outpatients; Polypharmacy; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Weight Gain | 2018 |
Aripiprazole reversed gastroparesis in a child with 1q21.1-q21.2 microdeletion.
Topics: Abnormalities, Multiple; Antipsychotic Agents; Aripiprazole; Child; Chromosome Deletion; Chromosomes, Human, Pair 1; Diagnosis, Differential; Gastroparesis; Humans; Male; Megalencephaly; Weight Gain | 2018 |
The effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and as adjunctive treatment in patients with major depressive disorder: an analysis of short-term and long-term studies.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Female; Humans; Longitudinal Studies; Male; Meta-Analysis as Topic; Middle Aged; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Thiophenes; Weight Gain | 2018 |
Weight-Change Trajectories of Pediatric Outpatients Treated with Risperidone or Aripiprazole in a Naturalistic Setting.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Body Mass Index; Body Weight; Child; Female; Humans; Male; Outpatients; Risperidone; Weight Gain | 2019 |
No Differences in Weight Gain Between Risperidone and Aripiprazole in Children and Adolescents After 12 Months.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Autism Spectrum Disorder; Body Mass Index; Child; Female; Humans; Male; Netherlands; Psychotic Disorders; Retrospective Studies; Risperidone; Time Factors; Weight Gain | 2019 |
Body mass index change in autism spectrum disorders: comparison of treatment with risperidone and aripiprazole.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Body Mass Index; Child; Child Development Disorders, Pervasive; Child, Preschool; Female; Humans; Irritable Mood; Male; Piperazines; Quinolones; Risperidone; Weight Gain; Young Adult | 2014 |
Different effects of bifeprunox, aripiprazole, and haloperidol on body weight gain, food and water intake, and locomotor activity in rats.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzoxazoles; Drinking Behavior; Feeding Behavior; Haloperidol; Male; Motor Activity; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Weight Gain | 2014 |
Aripiprazole long-acting injection: promising but more evidence needed.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Hyperprolactinemia; Injections, Intramuscular; Schizophrenia; Weight Gain | 2016 |
Therapeutic effectiveness and tolerability of aripiprazole as initial choice of treatment in first episode psychosis in an early intervention service: A one-year outcome study.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Energy Metabolism; Female; Follow-Up Studies; Humans; Male; Prospective Studies; Psychiatric Status Rating Scales; Psychotic Disorders; Treatment Outcome; Weight Gain; Young Adult | 2016 |
Reversible elevation of triglycerides in dual-diagnosis patients taking aripiprazole: a case series.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Diagnosis, Dual (Psychiatry); Humans; Hypertriglyceridemia; Mental Disorders; Piperazines; Quinolones; Substance-Related Disorders; Triglycerides; Weight Gain | 2008 |
Adjunctive aripiprazole decreased metabolic side effects of clozapine treatment.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Therapy, Combination; Humans; Male; Piperazines; Quinolones; Schizophrenia, Paranoid; Weight Gain | 2008 |
Aripiprazole for the management of olanzapine-induced weight gain.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Weight; Central Nervous System Agents; Cholesterol; Drug Therapy, Combination; Female; Glucose; Humans; Male; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Treatment Outcome; Triglycerides; Weight Gain | 2009 |
Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Composition; Child; Child, Preschool; Cohort Studies; Dibenzothiazepines; Female; Humans; Lipid Metabolism; Lipids; Male; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risk; Risperidone; Weight Gain | 2009 |
Pathological gambling and compulsive eating associated with aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Compulsive Behavior; Dose-Response Relationship, Drug; Eating; Female; Gambling; Humans; Middle Aged; Piperazines; Quinolones; Receptors, Dopamine D3; Schizophrenia; Weight Gain | 2010 |
Second-generation antipsychotics cause weight gain in youths.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Child, Preschool; Dibenzothiazepines; Humans; Olanzapine; Overweight; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Weight Gain | 2010 |
What is the mechanism for aripiprazole's effect on reducing olanzapine-associated obesity?
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Controlled Clinical Trials as Topic; Double-Blind Method; Humans; Obesity; Olanzapine; Piperazines; Quinolones; Schizophrenia; Weight Gain | 2010 |
A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone.
Topics: Age Factors; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Body Weight; Dibenzothiazepines; Female; Humans; Inpatients; Male; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Retrospective Studies; Risk; Risk Factors; Risperidone; Schizophrenia; Sex Factors; Time Factors; Weight Gain | 2011 |
Use of aripiprazole in adolescents with a history of lupus-associated psychosis and refractory psychiatric manifestations.
Topics: Adolescent; Adrenal Cortex Hormones; Antipsychotic Agents; Aripiprazole; Dyslipidemias; Female; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Lupus Vasculitis, Central Nervous System; Neuropsychological Tests; Piperazines; Psychotic Disorders; Quinolones; Remission Induction; Treatment Outcome; Weight Gain | 2011 |
Aripiprazole-related body-weight gain and nutritional counseling.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Piperazines; Quinolones; Schizophrenia; Weight Gain | 2011 |
Olanzapine, but not aripiprazole, weight-independently elevates serum triglycerides and activates lipogenic gene expression in female rats.
Topics: Adipose Tissue; Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Weight; Female; Gene Expression Regulation; Hyperphagia; Lipid Metabolism; Lipogenesis; Olanzapine; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Triglycerides; Weight Gain | 2012 |
Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs.
Topics: Adiponectin; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Body Mass Index; Body Weight; Female; Humans; Lipids; Male; Middle Aged; Obesity; Olanzapine; Piperazines; Prospective Studies; Psychotic Disorders; Quinolones; Weight Gain | 2013 |
[Expectations and developments in atypical antipsychotics].
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Clozapine; Diabetes Complications; Haloperidol; Humans; Obesity; Olanzapine; Piperazines; Quinolones; Risk Factors; Schizophrenia; Weight Gain | 2004 |
Characterisation of olanzapine-induced weight gain and effect of aripiprazole vs olanzapine on body weight and prolactin secretion in female rats.
Topics: Animals; Aripiprazole; Benzodiazepines; Body Weight; Cholesterol, HDL; Fatty Acids, Nonesterified; Female; Olanzapine; Piperazines; Prolactin; Quinolones; Rats; Rats, Sprague-Dawley; Rats, Wistar; Weight Gain | 2005 |
Second generation antipsychotics--aripiprazole revisited.
Topics: Antipsychotic Agents; Aripiprazole; Costs and Cost Analysis; Economics, Pharmaceutical; Humans; Piperazines; Quinolones; Schizophrenia; Weight Gain | 2005 |
Elevated lipase and diabetic ketoacidosis associated with aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Diabetic Ketoacidosis; Humans; Lipase; Male; Piperazines; Quinolones; Schizophrenia; Weight Gain | 2006 |
Reversal of antipsychotic-induced hyperprolactinemia, weight gain, and dyslipidemia by aripiprazole: A case report.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dyslipidemias; Female; Humans; Hyperprolactinemia; Obesity; Piperazines; Quinolones; Risperidone; Schizophrenia, Paranoid; Treatment Outcome; Weight Gain | 2006 |
Efficacy with high-dose aripiprazole after olanzapine-related metabolic disturbances.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Humans; Male; Metabolic Diseases; Olanzapine; Piperazines; Quinolones; Schizophrenia; Weight Gain | 2006 |
Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain: a pilot study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucose Tolerance Test; Humans; Insulin Resistance; Lipids; Lipoproteins; Male; Metabolism; Middle Aged; Pilot Projects; Piperazines; Quality of Life; Quinolones; Risk Factors; Schizophrenia; Schizophrenic Psychology; Weight Gain | 2007 |
Aripiprazole improves metabolic adversity in olanzapine-treated schizophrenic patients.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Appetite; Aripiprazole; Benzodiazepines; Drug Therapy, Combination; Female; Humans; Male; Metabolic Diseases; Obesity; Olanzapine; Piperazines; Quinolones; Schizophrenia; Weight Gain | 2007 |
Ziprasidone and aripiprazole attenuate olanzapine-induced hyperphagia in rats.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Eating; Female; Hyperphagia; Motor Activity; Olanzapine; Piperazines; Quinolones; Rats; Thiazoles; Weight Gain | 2008 |
Short- and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression.
Topics: Adipose Tissue; Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Eating; Female; Haloperidol; Olanzapine; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Receptors, Histamine H1; RNA, Messenger; Time Factors; Ventromedial Hypothalamic Nucleus; Weight Gain | 2008 |